Industry
Biotechnology
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 10:58 am
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:21 pm
Portfolio Pulse from Vandana Singh
May 29, 2024 | 7:33 pm
Portfolio Pulse from Avi Kapoor
May 29, 2024 | 5:28 pm
Portfolio Pulse from Avi Kapoor
May 29, 2024 | 2:17 pm
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 12:12 pm
Portfolio Pulse from Benzinga Insights
May 29, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 11:48 am
Portfolio Pulse from Benzinga Newsdesk
May 29, 2024 | 10:36 am
Portfolio Pulse from Benzinga Newsdesk
May 28, 2024 | 8:18 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.